IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+11.32%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$359M
AUM Growth
+$359M
(+3.2%)
Cap. Flow
-$3.33M
Cap. Flow
% of AUM
-0.93%
Top 10 Holdings %
Top 10 Hldgs %
38.59%
Holding
92
New
21
Increased
23
Reduced
17
Closed
21
Top Buys
| 1 |
McKesson
MCK
|
$13.7M |
| 2 |
Centene
CNC
|
$10.3M |
| 3 |
Abbott
ABT
|
$9.85M |
| 4 |
Biogen
BIIB
|
$8.4M |
| 5 |
AMED
Amedisys
AMED
|
$8.09M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$17.9M |
| 2 |
Medtronic
MDT
|
$10M |
| 3 |
Hologic
HOLX
|
$8.86M |
| 4 |
Zimmer Biomet
ZBH
|
$8.78M |
| 5 |
Acadia Healthcare
ACHC
|
$8.19M |
Sector Composition
| 1 | Healthcare | 97.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
AstraZeneca
AZN
$255B
| $5.83M | 1.61% |
+100,000
| New | +$5.83M |
|
27
Apellis Pharmaceuticals
APLS
$3.51B
| $5.67M | 1.57% |
120,000
-70,000
| -37% | -$3.31M |
|
|
ONEM
28
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $4.83M | 1.34% |
+275,000
| New | +$4.83M |
|
29
iRhythm Technologies
IRTC
$5.67B
| $4.71M | 1.3% |
+40,000
| New | +$4.71M |
|
30
Denali Therapeutics
DNLI
$2.24B
| $4.46M | 1.23% |
100,000
+25,000
| +33% | +$1.12M |
|
31
GSK
GSK
$79.5B
| $4.41M | 1.22% |
+100,000
| New | +$4.41M |
|
32
BioMarin Pharmaceuticals
BMRN
$11.3B
| $4.24M | 1.17% |
48,000
+30,000
| +167% | +$2.65M |
|
33
SI-BONE Inc
SIBN
$698M
| $3.89M | 1.08% |
175,000
+5,000
| +3% | +$111K |
|
34
Alnylam Pharmaceuticals
ALNY
$58.6B
| $3.39M | 0.94% |
20,000
-5,000
| -20% | -$848K |
|
35
Agilon Health
AGL
$501M
| $3.38M | 0.93% |
125,000
-55,000
| -31% | -$1.49M |
|
36
Arrowhead Research
ARWR
$3.84B
| $3.32M | 0.92% |
+50,000
| New | +$3.32M |
|
|
HZNP
37
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.23M | 0.89% |
30,000
-30,000
| -50% | -$3.23M |
|
38
Atara Biotherapeutics
ATRA
$88M
| $3.15M | 0.87% |
200,000
| – | – |
|
39
Masimo
MASI
$7.41B
| $2.93M | 0.81% |
+10,000
| New | +$2.93M |
|
40
Aclaris Therapeutics
ACRS
$219M
| $2.91M | 0.8% |
200,000
+15,000
| +8% | +$218K |
|
|
NVRO
41
DELISTED
NEVRO CORP.
NVRO
| $2.84M | 0.79% |
35,000
+5,000
| +17% | +$405K |
|
42
Avalo Therapeutics
AVTX
$136M
| $2.76M | 0.76% |
1,625,000
| – | – |
|
|
RETA
43
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.72M | 0.75% |
103,000
+68,000
| +194% | +$1.79M |
|
44
Replimune Group
REPL
$458M
| $2.71M | 0.75% |
100,000
+10,000
| +11% | +$271K |
|
45
Regenxbio
RGNX
$491M
| $2.45M | 0.68% |
75,000
+20,000
| +36% | +$654K |
|
46
Arcturus Therapeutics
ARCT
$462M
| $2.41M | 0.67% |
65,000
-20,000
| -24% | -$740K |
|
|
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
| $2.33M | 0.64% |
+50,000
| New | +$2.33M |
|
48
Incyte
INCY
$17B
| $2.2M | 0.61% |
+30,000
| New | +$2.2M |
|
49
Insmed
INSM
$30.3B
| $2.18M | 0.6% |
80,000
-20,000
| -20% | -$545K |
|
50
MacroGenics
MGNX
$120M
| $2.09M | 0.58% |
130,000
-30,000
| -19% | -$482K |
|